A Phase I/II Trial to Preserve Residual Insulin Secretion in Children With Recent Onset Type 1 Diabetes by Giving Verapamil

Condition(s) studied

Investigational drug(s) / intervention(s)

Verapamil (Part A): Verapamil 3-6mg/kg body weight and 24 hrs

Placebo: Placebo given in part B, the comparator arm of the double blind randomized trial

Study summary

The objective of this trial is first to evaluate safety and then the effect on preservation of residual beta cell function also clinical efficacy by treatment with Verapamil in children with recent onset Type 1 diabetes.

Patients are included with the following inclusion criteria;

* Informed consent given by patients and caregivers/parents Type 1 diabetes according to the ADA classification within the previous 3 months at the time of screening
* Age 4.00 -9.99 years at Diagnosis of Type 1 diabetes
* Fasting C-peptide \>0.12 nmol/ml
* Elevated levels of any diabetes-related antibody/ies (eg GADA, IAA, IA-2A, ZnT8A ) is/are present.

While they are not allowed to participate if they eg have previous cardiac problems or abnormal ECG.

The study is a Phase I/II trial, with two parts: A. 6 patients participate in an open controlled study without any placebo with the primary aim to evaluate safety. After a baseline evaluation including ECG, physical examination, mixed Meal Tolerance Test evaluating residual beta cell fuction, these patients will be treated for 12 months with Verapamil 3-6 mg/kg body weight/24 hrs, divided into two daily doses. When these 6 patients have been followed for 6 months, and safety and tolerability is regarded as good, part B will start: In part B the next 30 patients will be randomized 1:1 in a double-blind placebo-controlled study into two arms: 15 patients will receive active treatment for 12 months with Verapamil 3-6 mg/kg body weight/24 hrs divided into two daily oral doses, while 15 patients will receive placebo in two daily doses for 12 months. Efficacy will be evaluated with MMTT and clinical response ( insulin dose/kg body weight/24 hrs, HbA1c, and CGM data on Glucose Time in Range), from baseline and after 12 and 24 months.

There is a great benefit of preservation of residual insulin secretion, and therefore therapies aiming at preservation of this function justifies treatments that are quite heavy, even dangerous and expensive.

In this study the investigators will use oral Verapamil, a drug which is used as antihypertensive treatment in different ages, even in children in the neonatal period, with limited adverse events and risks. Verapamil treatment has shown encouraging results preserving beta cell function in Type 1 diabetes in adults, and the investigators expect to get similar positive effects also in young children, in whom so far no immune intervention has shown efficacy.

Eligibility

Primary outcome measure(s)

• Change in C-peptide AUCmean 0-120 min) during an MMTT from baseline to month 24. — 24 months
• Number of participants with treatment-related adverse events as assessed by CTCAE v4.0". — 24 months
  Adverse events are registered after history, clinical examinations, laboratory tests and ECG. Patients and parents are interviewed about tolerability

Trial sites (2)

Other trials for the same condition